How did body mass index relate to survival across kidney cancer treatments?

Since the previous research note · Changed direction

Track continuity

Since the previous research note: What can body mass index tell us about immunotherapy outcomes?

Previous expectation: A validated BMI-related measure might help clinicians anticipate checkpoint-treatment benefit and immune side effects across patient groups.

What this study adds: This 2024 synthesis narrowed the question to first-line metastatic kidney cancer and found that the higher-BMI overall-survival association appeared in cohorts receiving checkpoint therapy with a targeted drug, but was not detected in predominantly checkpoint-only cohorts. Its progression finding also points away from a single favorable BMI story.

---

What changed in this study

A survival association appeared in one treatment grouping

In people with metastatic renal cell carcinoma, a higher pretreatment body mass index (BMI) was associated with longer overall survival in studies where first-line treatment combined an immune checkpoint inhibitor with a targeted drug. In studies using predominantly checkpoint-inhibitor-only treatment, the review did not find a clear overall-survival difference between BMI groups. BMI is calculated from weight relative to height; it is a broad measure, not a direct reading of muscle, fat distribution, or health.

The 2024 systematic review and meta-analysis pooled seven studies involving 2,517 people. Across the adjusted overall-survival results, the hazard ratio for higher versus lower BMI was 0.75 (95% confidence interval 0.59–0.95). In plain terms, the estimated rate of death over follow-up was lower in the higher-BMI groups after adjustment for factors considered in the contributing studies. A hazard ratio compares event rates over time; it does not mean that an individual’s chance of survival rose by 25 percentage points.

The treatment subgroups help explain why the pooled result needs context. For studies of checkpoint inhibitors combined with a tyrosine kinase inhibitor (TKI), the adjusted hazard ratio was 0.71 (95% CI 0.55–0.92), an association with lower death rates in the higher-BMI group. In the predominantly checkpoint-only subgroup, the estimate was 1.02 (95% CI 0.56–1.87), close to no difference, with uncertainty broad enough to include meaningfully different outcomes. These are comparisons between BMI groups in the included studies, not tests of which treatment would work better for a particular person.

Seven studies combined different treatment mixes

The authors searched MEDLINE, Embase, and the Cochrane Library on October 12, 2023. They found 731 records, removed 132 duplicates, screened 599 records, and included seven studies in the final analysis. The studies comprised two phase III randomized trials, four retrospective studies, and one conference abstract. The treatment was not assigned according to BMI, so the review compared outcomes among people who already fell into different BMI categories.

The authors grouped studies by the treatment most patients received. Four were classed as predominantly checkpoint-only, and two as predominantly checkpoint inhibitor plus TKI; details for six studies described their regimens. Those labels were not perfectly uniform. For example, one checkpoint-only cohort included 73.5% of patients on nivolumab plus ipilimumab, while one checkpoint-plus-TKI cohort had 52% receiving that combination approach. The groups therefore capture the predominant treatment pattern, not two completely separated treatment populations.

BMI cutoffs also varied among studies, including thresholds of 18.5, 25, and 30 kg/m². The researchers used adjusted estimates where available, but studies differed in which patient characteristics they accounted for. That variation matters because BMI could be connected to other features that influence survival, and adjustment cannot remove every source of difference between groups.

The focus on first-line therapy narrows an important complication. Treatment received before BMI is measured can change what that measurement represents: TKIs have been associated with changes in muscle, fat, and weight. A BMI recorded after such treatment may reflect both a person’s earlier body composition and changes during care. The review’s first-line focus reduces that particular ambiguity, but the treatment cohorts and patient histories still were not identical.

Survival, progression, and tumor response did not tell the same story

Overall survival measures time until death from any cause. Progression-free survival tracks how long a person lives without the cancer progressing, while objective response records whether a tumor shrinks enough to meet a study’s response criteria. These outcomes describe different parts of the treatment experience, so a BMI association for one does not automatically carry over to the others.

For progression-free survival, adjusted results were available chiefly from studies of predominantly checkpoint-only treatment. The adjusted hazard ratio for higher versus lower BMI was 1.67 (95% CI 1.14–2.45), favoring the lower-BMI group for time without progression. Because comparable adjusted progression results were not available for both treatment groupings, this finding cannot show whether the relationship would differ under checkpoint-plus-TKI treatment.

The response-rate comparison was less conclusive. Its relative risk estimate was 0.90 (95% CI 0.47–1.73), with substantial variation across studies. The interval includes outcomes that could favor either BMI group, and the analysis included checkpoint-only studies rather than a parallel comparison across both treatment types. The evidence therefore does not establish a consistent BMI pattern for tumor response.

A separate overall-survival calculation also produced a less decisive result. Some studies supplied event counts rather than the time-to-event hazard ratios used in the main analysis. For those data, the relative risk was 0.88 (95% CI 0.67–1.16), which did not show a clear difference between BMI groups. This comparison does not erase the adjusted hazard-ratio finding, but it shows that the apparent association was not reproduced as clearly in every way the studies reported survival.

A possible biological explanation remains a hypothesis

The authors proposed that blood-vessel growth may help explain why BMI’s association looked different in the checkpoint-plus-TKI studies. They discussed the possibility that tumors in people with higher BMI may have more angiogenesis-related activity, and that a TKI could matter in tumors with those signals because these drugs target pathways involved in blood-vessel growth. This is one proposed interpretation of the subgroup pattern; the meta-analysis did not test whether that mechanism caused it.

BMI alone cannot identify whether a person has more muscle, where fat is distributed, how physically resilient they are, or which tumor pathways are active. It may reflect a combination of body composition and general health, but it cannot separate those possibilities. A measurement that bundles several characteristics can be associated with outcomes without revealing which characteristic is responsible.

The evidence is too limited to select treatment or change weight

Seven studies provide a useful comparison, but they are a small base for drawing treatment-specific conclusions. The authors’ risk assessment found high risk of bias in the confounding and statistical-analysis domains for four of the seven studies. Two had moderate confounding concerns related to variation in treatment regimens. The evidence also mixed prospective and retrospective designs, different BMI thresholds, and different levels of adjustment. A pooled number can summarize these studies, but it cannot make their differences disappear.

Overall survival may also reflect care received after the first-line treatment being studied. The authors noted that follow-up was short and that later treatment could contribute to survival outcomes. Along with differences in patient characteristics, these factors leave open whether BMI itself, another feature associated with BMI, or the treatment mix accounts for the observed pattern.

Most importantly, an association within a treatment group is not proof that BMI predicts which regimen gives an individual greater benefit. Showing that would require evidence that directly distinguishes a BMI-related difference in general prognosis from a difference in relative benefit between treatments, and that adds reliable information about individual patients. This review does not validate such a prediction tool. Nor does it show that increasing or reducing weight changes cancer outcomes; its comparisons are not a basis for weight advice.

How this could sharpen kidney cancer treatment conversations

Better validated, treatment-specific information about body composition could eventually help oncology teams give patients more tailored expectations before first-line therapy for metastatic kidney cancer. That use depends on studies separating general prognosis from differences in benefit between regimens, and on measures that add reliable information for individual patients. Until those steps are met, BMI remains an observed clue in a small, varied evidence base, not a guide to choosing a treatment.

Key Sources

• Primary source: Impact of pretreatment body mass index on clinical outcomes in patients with metastatic renal cell carcinoma receiving first-line immune checkpoint inhibitor-based therapy: A systematic review and meta-analysis.
  DOI or Journal Page · Review or Meta-Analysis · 2024-09-01